Micha T Maeder1, Werner Strobel2, Michael Christ3, John Todd4, Joel Estis4, Karin Wildi5, Gregor Thalmann5, Jonas Hilti5, Martin Brutsche6, Raphael Twerenbold5, Hans Rickli7, Christian Mueller5. 1. Division of Cardiology, University Hospital Basel, Switzerland; Division of Cardiology, Kantonsspital St. Gallen, Switzerland. Electronic address: micha.maeder@kssg.ch. 2. Division of Respiratory Medicine, University Hospital Basel, Switzerland. 3. Division of Internal Medicine, University Hospital Basel, Switzerland; Department of Emergency and Critical Care Medicine, City Hospital Nuremberg, Germany. 4. Singulex, Inc., Alameda, CA, USA. 5. Division of Cardiology, University Hospital Basel, Switzerland; Division of Internal Medicine, University Hospital Basel, Switzerland. 6. Division of Respiratory Medicine, University Hospital Basel, Switzerland; Division of Respiratory Medicine, Kantonsspital St. Gallen, Switzerland. 7. Division of Cardiology, Kantonsspital St. Gallen, Switzerland.
Abstract
OBJECTIVES: The pathophysiological links between obstructive sleep apnea syndrome (OSAS) and cardiovascular mortality are incompletely understood. We aimed to contribute to a better characterization by using comprehensive biomarker profiling quantifying hemodynamic cardiac stress, cardiomyocyte injury, inflammation, endothelial function, matrix turnover and metabolism. DESIGN AND METHODS: In 65 patients with moderate or severe OSAS [apnea-hypopnea index (AHI) 39±20/h] and 33 patients with no or mild OSAS (AHI 8+4/h), B-type natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), high-sensitivity cardiac troponin I (hs-cTnI), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and insulin were measured before and after sleep. In a subgroup measurements were repeated in a second night with continuous positive airway pressure (CPAP). RESULTS: Patients with moderate/severe OSAS had higher insulin before sleep [median (interquartile range), 36.4 (21.9-52.1) vs. 20.8 (10.6-32.8)mU/mL; p=0.006], higher IL-6 after sleep [1.00 (0.73-1.58) vs. 0.72 (0.48-0.94)pg/mL; p=0.005], and larger relative overnight reduction in BNP [-9 (-35-0) vs. -3 (-21-13)%; p=0.04] than those with mild/no OSAS. Insulin before sleep was the only independent predictor of moderate/severe OSAS. Insulin before and IL-6 after sleep were independent predictors of severe OSAS, and when combined provided high diagnostic accuracy for severe OSAS (area under the receiver operator characteristic curve 0.80; 95%-confidence interval 0.69-0.91). In contrast, there were no significant differences in NT-proBNP, hs-cTnI, VEGF, and MMP-9 between moderate/severe and mild/no OSAS. Short-term CPAP had no impact on biomarker concentrations before and after sleep. CONCLUSIONS: Significant OSAS is characterized by a distinct biomarker profile including high insulin before and high IL-6 after sleep.
OBJECTIVES: The pathophysiological links between obstructive sleep apnea syndrome (OSAS) and cardiovascular mortality are incompletely understood. We aimed to contribute to a better characterization by using comprehensive biomarker profiling quantifying hemodynamic cardiac stress, cardiomyocyte injury, inflammation, endothelial function, matrix turnover and metabolism. DESIGN AND METHODS: In 65 patients with moderate or severe OSAS [apnea-hypopnea index (AHI) 39±20/h] and 33 patients with no or mild OSAS (AHI 8+4/h), B-type natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), high-sensitivity cardiac troponin I (hs-cTnI), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and insulin were measured before and after sleep. In a subgroup measurements were repeated in a second night with continuous positive airway pressure (CPAP). RESULTS:Patients with moderate/severe OSAS had higher insulin before sleep [median (interquartile range), 36.4 (21.9-52.1) vs. 20.8 (10.6-32.8)mU/mL; p=0.006], higher IL-6 after sleep [1.00 (0.73-1.58) vs. 0.72 (0.48-0.94)pg/mL; p=0.005], and larger relative overnight reduction in BNP [-9 (-35-0) vs. -3 (-21-13)%; p=0.04] than those with mild/no OSAS. Insulin before sleep was the only independent predictor of moderate/severe OSAS. Insulin before and IL-6 after sleep were independent predictors of severe OSAS, and when combined provided high diagnostic accuracy for severe OSAS (area under the receiver operator characteristic curve 0.80; 95%-confidence interval 0.69-0.91). In contrast, there were no significant differences in NT-proBNP, hs-cTnI, VEGF, and MMP-9 between moderate/severe and mild/no OSAS. Short-term CPAP had no impact on biomarker concentrations before and after sleep. CONCLUSIONS: Significant OSAS is characterized by a distinct biomarker profile including high insulin before and high IL-6 after sleep.
Authors: Anne E Sanders; Greg K Essick; James D Beck; Jianwen Cai; Shirley Beaver; Tracy L Finlayson; Phyllis C Zee; Jose S Loredo; Alberto R Ramos; Richard H Singer; Monik C Jimenez; Janice M Barnhart; Susan Redline Journal: Sleep Date: 2015-08-01 Impact factor: 5.849
Authors: M Melanie Lyons; Nitin Y Bhatt; Elizabeth Kneeland-Szanto; Brendan T Keenan; Joanne Pechar; Branden Stearns; Nabil M Elkassabany; Stavros G Memtsoudis; Allan I Pack; Indira Gurubhagavatula Journal: Biomark Med Date: 2016 Impact factor: 2.851
Authors: Janet M Mullington; Sabra M Abbott; Judith E Carroll; Christopher J Davis; Derk-Jan Dijk; David F Dinges; Philip R Gehrman; Geoffrey S Ginsburg; David Gozal; Monika Haack; Diane C Lim; Madalina Macrea; Allan I Pack; David T Plante; Jennifer A Teske; Phyllis C Zee Journal: Sleep Date: 2016-04-01 Impact factor: 5.849
Authors: Macy M S Lui; H F Tse; Judith C W Mak; David C L Lam; Carmen W S Chan; Peony W C Chong; Mary S M Ip Journal: J Clin Sleep Med Date: 2018-11-15 Impact factor: 4.062